Ablevia Biotech

Ablevia Biotech is a Vienna-based biopharmaceutical company developing a transformative platform for the selective clearance of pathogenic antibodies from the circulation. Their core technology employs proprietary Bi-specific Antibody-binding Molecules (BAMs) designed to neutralize and eliminate specific autoantibodies by redirecting them to the liver for rapid degradation. This targeted approach offers a potential alternative to broad immunosuppressive therapies and invasive procedures like plasmapheresis. The company's lead program is currently in the pre-clinical stage, focusing on the treatment of Myasthenia Gravis. Ablevia aims to expand its pipeline to address a wide range of autoimmune and alloimmune disorders driven by harmful antibodies.